Isomerase Therapeutics Limited is a UK-based biotechnology company focused on the development and commercialization of novel therapeutics utilizing isomerization chemistry. Established in 2012, the company specializes in discovering, optimizing, and producing innovative drug candidates with potential applications across various therapeutic areas including oncology and immunology. Currently, Isomerase’s core activities center around proprietary intellectual property – primarily focusing on research and development leveraging isomerization reactions to enhance drug efficacy or improve pharmacokinetic properties. The company emphasizes a collaborative approach, partnering with academic institutions and pharmaceutical companies for clinical trials and early-stage product advancement. Isomerase operates within the SIC codes of -72110 (Research and experimental development on biotechnology) and potentially other relevant industries such as pharmaceuticals, medical devices, and diagnostics depending on specific project activities. The company is currently a Skilled Worker visa holder with an A rating, indicating strong capabilities and potential for growth. The company’s international presence includes collaborations with research centers in Europe and North America, demonstrating a strategic focus on global market access. Isomerase Therapeutics Ltd. maintains a stock symbol of ISMT.

Isomerase Therapeutics Limited is a UK-based biotechnology company focused on the development and commercialization of novel therapeutics utilizing isomerization chemistry. Established in 2012, the company specializes in discovering, optimizing, and producing innovative drug candidates with potential applications across various therapeutic areas including oncology and immunology. Currently, Isomerase’s core activities center around proprietary intellectual property – primarily focusing on research and development leveraging isomerization reactions to enhance drug efficacy or improve pharmacokinetic properties. The company emphasizes a collaborative approach, partnering with academic institutions and pharmaceutical companies for clinical trials and early-stage product advancement. Isomerase operates within the SIC codes of -72110 (Research and experimental development on biotechnology) and potentially other relevant industries such as pharmaceuticals, medical devices, and diagnostics depending on specific project activities. The company is currently a Skilled Worker visa holder with an A rating, indicating strong capabilities and potential for growth. The company’s international presence includes collaborations with research centers in Europe and North America, demonstrating a strategic focus on global market access. Isomerase Therapeutics Ltd. maintains a stock symbol of ISMT.